Abstract:Background: Excessive inflammation results in severe tissue damage as well as serious acute or chronic disorders, and extensive research has focused on finding new anti-inflammatory hit compounds with safety and efficacy profiles from natural products. As promising therapeutic entities for the treatment of inflammation-related diseases, fusaproliferin and its analogs have attracted great interest. However, the underlying anti-inflammatory mechanism is still poorly understood and deserves to be further investigated. Methods: For the estimation of the anti-inflammatory activity of fusaproliferin (1) and its analogs (2-4) in vitro and in vivo, lipopolysaccharide (LPS)-induced RAW264.7 macrophages and zebrafish embryos were employed. Then, transcriptome analysis was applied to guide subsequent western blot analysis of critical proteins in related signaling pathways. Surface plasmon resonance assays (SPR) combined with molecular docking analyses were finally applied to evaluate the affinity interactions between 1-4 and TLR4 and provide a possible interpretation of the downregulation of related signaling pathways. Results: 1-4 significantly attenuated the production of inflammatory messengers, including nitric oxide (NO), reactive oxygen species (ROS), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-alpha), and interleukin-1 beta (IL-1 beta), as well as nitric oxide synthase (iNOS) andcyclooxygenase2 (COX-2), in LPS-induced RAW264.7 macrophages. Transcriptome analyses based on RNA-seq indicated the ability of compound 1 to reverse LPS stimulation and the nuclear factor kappa-B (NF-kappa B) and mitogen-activated protein kinase (MAPKs) signaling pathways contribute to the anti-inflammatory process. Experimental verification at the protein level revealed that 1 can inhibit the activation of inhibitor of NF-kappa B kinase (IKK), degradation of inhibitor of NF-kappa B (I.B), and phosphorylation of NF-kappa B and reduce nuclear translocation of NF kappa B. 1 also decreased the phosphorylation of MAPKs, including p38, extracellular regulated protein kinases (ERK), and c-Jun N-terminal kinase (JNK). SPR assays andmolecular docking results indicated that 1-4 exhibited affinity for the TLR4 protein with KD values of 23.5-29.3 mu M. Conclusion: Fusaproliferin and its analogs can be hit compounds for the treatment of inflammation-associated diseases.

Function and inhibition of P38 MAP kinase signaling: Targeting multiple inflammation diseases

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Recent Advance on P38 Mitogen-Activated Protein Kinases Inhibitors

The journey of p38 MAP kinase inhibitors: From bench to bedside in treating inflammatory diseases

Functional Roles of p38 Mitogen-Activated Protein Kinase in Macrophage-Mediated Inflammatory Responses

p38 MAPK signalling cascades and inflammatory disease

Inhibition of Inflammation by a P38 MAP Kinase Targeted Cell Permeable Peptide

Novel Strategies for Inhibition of the P38 MAPK Pathway.

p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics

Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy

Research progress on the role and inhibitors of Keap1 signaling pathway in inflammation

Ligand-based 3D pharmacophore design, virtual screening and molecular docking for novel p38 MAPK inhibitors

Integrative Proteomic Analysis of Multiple Posttranslational Modifications in Inflammatory Response

p38 MAPK inhibits autophagy and promotes microglial inflammatory responses by phosphorylating ULK1

Targeting MAPK signaling: A promising approach for treating inflammatory lung disease

Feedback Control of MKP-1 Expression by P38

A Novel Chromone Derivative With Anti-Inflammatory Property Via Inhibition Of Ros-Dependent Activation Of Traf6-Ask1-P38 Pathway

[Controlling Arachidonic Acid Metabolic Network: from Single- to Multi-Target Inhibitors of Key Enzymes].

Investigation of the Anti-Inflammatory Activity of Fusaproliferin Analogues Guided by Transcriptome Analysis

p38 MAPK Activity Is Required to Prevent Hyperactivation of NLRP3 Inflammasome

Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies